 |
Tranzyme Pharma Receives IND Clearance for Its Oral Ghrelin Agonist, TZP-102, for the Treatment of Gastroparesis
Jan 29, 2008
|
6.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (January 29, 2008) - Tranzyme Pharma announced today that the US Food and Drug Administration (FDA) completed its review of the Company's Investigational New Drug (IND) application for TZP-102, Tranzyme's second drug candidate to reach clinical development.
...
|
|
Tranzyme Pharma to Present at the 26th Annual JPMorgan Healthcare Conference
Dec 19, 2007
|
4.8 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (December 19, 2007) Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal (GI) and metabolic diseases, announced today that Vipin K. Garg, Ph.D., President and CEO, will present at the upcoming 26th...
|
|
Tranzyme Pharma Closes New $20 Million Financing
Nov 1, 2007
|
8.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (November 1, 2007) - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal (GI) and metabolic diseases, announced today that it has completed a new round of private financing, raising a total of $20 million....
|
|
Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial for the Treatment of Severe Gastroparesis
Oct 30, 2007
|
7.3 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (October 30, 2007) - Tranzyme Pharma today announced the initiation of a Phase IIb clinical trial of its potent intravenous ghrelin agonist, TZP-101, for the management of severe gastroparesis. TZP-101 is a first-in-class prokinetic agent under development for the treatment o...
|
|
Tranzyme Pharma's Motilin Antagonist TZP-201 Shows Potential for Preventing and Treating Chemotherapy-Induced Diarrhea (CID)
Oct 24, 2007
|
6.8 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (October 24, 2007) - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, announced today that its Senior Vice President of Research and Preclinical Development, Dr. Helmut Thomas, w...
|
|
Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial with its Novel Ghrelin Agonist, TZP-101, for Post-Operative Ileus
Jul 26, 2007
|
7.2 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (July 26, 2007) - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, today announced the initiation of a Phase IIb clinical trial of its investigational drug, TZP-101, for the mana...
|
|
Tranzyme Pharma Receives FDA Fast Track Designation for its Novel Ghrelin Agonist, TZP-101, for the Treatment of Severe Gastroparesis
Jul 12, 2007
|
6.5 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (July 12, 2007) - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, today announced that the company has received fast track designation for its novel ghrelin agonist, TZP-101, fo...
|
|
Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Jun 26, 2007
|
7.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (June 26, 2007) - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, today announced positive results for its novel ghrelin agonist, TZP-101, in accelerating gastric emptying in di...
|
|
Tranzyme Pharma Announces Issuance of European Patent Protecting Company's Novel Macrocyclic Chemistry
Dec 13, 2006
|
5.8 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (December 13, 2006) - Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) and metabolic disorders, announced today the issuance of a European patent (EP 1 218 403) entitled "Combinatoria...
|
|
Tranzyme Pharma Expands Clinical Program of its Novel Ghrelin Agonist, TZP-101, to Include Patients with Gastroparesis
Sep 21, 2006
|
6.2 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (September 21, 2006) - Tranzyme Pharma announced today that the Company has amended the IND for its novel small molecule ghrelin agonist, TZP-101, to include patients with gastroparesis. Tranzyme has been developing TZP-101 as a potent prokinetic agent for the treatment of po...
|
|
Tranzyme Pharma Appoints New Vice President of Business Development & Licensing
Aug 10, 2006
|
5.9 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (August 10, 2006) -Tranzyme Pharma, a leading biopharmaceutical company developing novel small molecule therapeutics for the treatment of gastrointestinal (GI) and metabolic diseases, announced today the appointment of Eric M. Nelson, Ph.D., as the Company’s Vice Presid...
|
|
Tranzyme Pharma Receives Notice of Allowance from USPTO on Patent Protecting Company’s Macrocyclic Chemistry Technology
Jul 19, 2006
|
6.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (July 19, 2006) -Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) and metabolic disorders, announced today that the Company has received a Notice of Allowance from the U.S. Patent and...
|
|
Tranzyme Pharma Appoints Industry Veteran as Senior Vice President of Research and Preclinical Development
Jun 21, 2006
|
6.1 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (June 21, 2006) -Tranzyme Pharma, a leading biopharmaceutical company developing novel small molecule therapeutics for the treatment of gastrointestinal (GI) and metabolic diseases, announced today the appointment of Helmut Thomas, Ph.D., DABT, as the Company’s Senior V...
|
|
Tranzyme Pharma to Present New In Vivo Data on its Novel GI Compounds at Digestive Disease Week 2006
May 17, 2006
|
6.5 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (May 17, 2006) - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule therapeutics for the treatment of gastrointestinal (GI) and metabolic diseases, announced today that its Vice President of Drug Discovery, Dr. Graeme Fraser, will present results f...
|
|
Tranzyme Pharma Announces Successful Completion of Phase I Clinical Trial of its Novel Ghrelin Agonist, TZP-101
May 10, 2006
|
6.3 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (May 10, 2006) -Tranzyme Pharma announced today that it has successfully completed a Phase I clinical trial of its first drug candidate, TZP-101, a new chemical entity originating from the Company’s proprietary small molecule macrocyclic chemistry technology. TZP-101 is...
|
|
Tranzyme Pharma Receives IND Clearance for its Novel Ghrelin Agonist, TZP-101
Jan 10, 2006
|
6.9 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (January 10, 2006) -Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) and metabolic disorders, today announced that the U.S. Food and Drug Administration has cleared its Investigationa...
|
|
Tranzyme Pharma Appoints New Vice President of Clinical and Regulatory Affairs
Sep 20, 2005
|
5.7 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (September 20, 2005) - Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal disorders, announced today the appointment of Gordana Kosutic, M.D. as the Company’s new Vice President of Cli...
|
|
Tranzyme Pharma’s Ghrelin Agonist Demonstrates a Unique Selectivity Profile for the Treatment of Gastrointestinal Disorders
Jul 6, 2005
|
6.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (July 6, 2005) - Tranzyme Pharma Inc., a leading biopharmaceutical company developing small molecule therapeutics for the treatment of gastrointestinal (GI) disorders, announced today new and exciting efficacy data for TZP-101, the Company’s lead product for the treatme...
|
|
FierceBiotech Honors Tranzyme Pharma as One of the “Fierce 15” Biotech Companies of 2005
Jun 21, 2005
|
6.5 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C. and SHERBROOKE, Québec (21 June, 2005) - Tranzyme Pharma announced today that it has been named to FierceBiotech’s annual Fierce 15 list. This distinction honors Tranzyme as one of the top 15 emerging biotech companies for 2005. FierceBiotech, an internationally recognized email newsletter co...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
